F-Prime-backed start­up hopes to lever­age AI and a su­per­com­put­er to emerge in pro­tein mis­fold­ing field

3 years ago
Startups
Deals

Broad In­sti­tute's drug dis­cov­ery arm starts see­ing the fruit of its la­bor en­ter the clin­ic

3 years ago
R&D

Ever­est Med­i­cines reach­es its first peak in Chi­na with Trodelvy nod; Cy­cle­ri­on touts da­ta in small study

3 years ago
News Briefing

Blue­print Med­i­cines slips as it changes end­point for tri­al in aim to great­ly broad­en Ay­vak­it la­bel

3 years ago
R&D

Psy­che­delics start­up Eleu­sis ax­es SPAC deal, but CEO con­fi­dent its IV psilo­cy­bin ther­a­py will en­ter clin­ic next month

3 years ago
Financing
Deals

Aim­ing to har­ness the pow­er of mi­to­chon­dria, a Japan­ese start­up nets new fund­ing

3 years ago
Startups
Deals

Amarin fish­es for an­oth­er CFO as down­siz­ing takes hold; Cure­Vac makes a deal, then lines up No­var­tis ex­ec to lead ...

3 years ago
Peer Review

Along­side tiny da­ta drop, Cari­bou plans dose es­ca­la­tion for its first off-the-shelf CAR-T tri­al

3 years ago
R&D
Cell/Gene Tx

GSK de­clares a big win with pos­i­tive topline re­sults for its adult RSV vac­cine. But the ju­ry's still out on bot­tom ...

3 years ago
R&D

In sur­prise, FDA ad­comm votes unan­i­mous­ly in fa­vor of blue­bird's gene ther­a­py for rare dis­ease even with safe­ty ...

3 years ago
FDA+

#BIO22 sur­vey: The E100 as­sess the Nas­daq win­ter that is freez­ing out biotech. But hir­ing re­mains a top pri­or­i­ty

3 years ago
R&D

#BIO22: By the Num­bers: Af­ter the mu­sic died, you can see some en­cour­ag­ing signs on the M&A and li­cens­ing fronts. But ...

3 years ago
Deals

#BIO22: The bear mar­ket may be maul­ing biotech stocks, but the fun­da­men­tals still look good to re­al es­tate de­vel­op­ers

3 years ago
Financing
Deals

#BIO22: Are biotech buy­outs fi­nal­ly com­ing in­to vogue? Here's what to look for in H2 M&A

3 years ago
Financing
Deals

Roche's ROS1+ can­cer drug gets FDA green­light for Foun­da­tion Med­i­cine's com­pan­ion di­ag­nos­tic

3 years ago
Pharma
Diagnostics

Phar­ma groups de­cry Covid-19 vac­cine IP waiv­er ahead of Gene­va con­fer­ence

3 years ago
Pharma
Coronavirus

Sen­a­tors call on USP­TO to ad­dress phar­ma patent thick­ets be­fore they start

3 years ago
Pharma
Law

CDC writes first check in $1.1B Can­cer Moon­shot grant

3 years ago
Pharma

J&J ad­vances ‘Pos­i­tive­ly Fear­less’ HIV cam­paign, de­but­ing web­site and newest am­bas­sador

3 years ago
Pharma
Marketing

Man­u­fac­tur­ing roundup: Lon­za com­pletes man­u­fac­tur­ing fa­cil­i­ty in East­ern Ore­gon; Wal­mart and CVS part of mas­sive ...

3 years ago
Manufacturing

Sam­sung Bi­o­log­ics and No­var­tis ink man­u­fac­tur­ing con­tract worth $81M

3 years ago
Deals
Manufacturing

#BIO22: BIO chair Paul Hast­ings: 'I think peo­ple should speak their truth'

3 years ago
People
R&D

#BIO22: Com­ing to­geth­er at a crit­i­cal time, End­points News looks at the key met­rics on bio­phar­ma in a tur­bu­lent time

3 years ago
Bioregnum

Al­ny­lam boasts PhII win in kid­ney dis­ease cor­ner­stone of Re­gen­eron R&D block­buster deal

3 years ago
R&D
First page Previous page 515516517518519520521 Next page Last page
A service from the Financial Times